Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — H1 FY2024 Earnings Presentation
27 slides from Dr. Lal Pathlabs's earnings presentation, Nov 2, 2023
Slide 1: Exchange filing cover letter
November 02, 2023 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Earning
Slide 2: Dr. Lal PathLabs Limited Q2 & H1 FY24 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q2 & FH FY24 Results Presentation November 2, 2023
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentati
Slide 4: Table of Contents
Table of Contents DLPL- At a Glance 4 Q2’24 Performance Overview 5 Financials 6 Operating Highlights 7 Management Commentary 9 Corporate Overview 10 Shareholding 24 Contact Us 26 DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Company’s business operations remai
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance 15% 24% 120% 5,191 277 5,102 3 Year Revenue ROCE Equity Dividend for Pathology & Labs; Geographically Patient Service CAGR Excl. Cash & FY 22-23 Radiology tests; spread-out network Centers (PSC’s) Investments Comprehensive Test menu 70+ years of experience in 111 Mn pa
Slide 6: Q2'24 Performance Overview
Q2’24 Performance Overview Q2 FY24 Q2 FY23 12.6% Rs. 601 crore Revenue Rs. 534 crore 23.6% Rs. 178 crore EBITDA Rs. 144 crore 52.9% Rs. 111 crore PAT Rs. 72 crore +2% 21% SwasthFit 19% Contr. +361 Cr Rs. 780 crore Cash Rs. 419 crore Classification: Restricted 5 Classification: Restricted
Slide 7: Financials
Financials Particulars (Rs. Cr.) Q2 FY24 Q2 FY23 Gr % FH'24 FH'23 Gr % Revenue 601 534 12.6% 1,142 1,037 10.2% Operating Expenditure 424 390 818 775 EBITDA 178 144 23.6% 324 261 24.0% Margins 29.6% 26.9% 28.4% 25.2% Other Income 18 9 32 17 Depreciation 36 39 71 75 EBIT 160 114 40.6% 285 204 40.2% Ma
Slide 8: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +61 +2,007 +3,943 277 277 4,731 5,102 9,247 10,599 10,938 216 231 3,705 3,095 6,995 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 No. of Patients (Mn) No. of Samples (Mn) +39% +52% 27.3 26.9 66.0 72.3 19.4 20.3 1
Slide 9: Increasing DLPL reach in Tier 3+
Increasing DLPL reach in Tier 3+ Particulars FY20 FY21 FY22 FY 23 Revenue Tier 3+ 421 544 683 685 18% 15% Tier 3+ CAGR Total CAGR Total DLPL Revenue 1,330 1,581 2,087 2,,017 % Revenue from Tier 3+ 32% 34% 33% 34% +2% Contribution from Tier 3+ Infra Count in Tier 3+ Labs 60 64 69 70 +10 Labs CCs 1,76
Slide 10: Management Commentary
Management Commentary Commenting on the performance, (Hony) Brig. Dr. Commenting on the performance, Dr. Om Manchanda, Commenting on the performance, Mr. Bharath Arvind Lal, Executive Chairman said: Managing Director said: Uppiliappan, Chief Executive Officer said: “Dr. Lal PathLabs has been relentl
Slide 11: Corporate Overview
WIDENING “0:26 HORIZONS Ox Lat Pathlabs D (3) y SERVING BETTER Corporate Overview
Slide 12: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Established Established consumer healthcare brand in diagnostic services brand Pan-India 277 clinical labs (including National Reference Lab at Delhi and Well-positioned integrated Regional Reference labs at Kolkata, Bangalore & Mumbai), 5,102 coverage Patient Service Ce
Slide 13: Vision, Mission & Values
Vision, Mission & Values Be the most trusted Customer First healthcare partner, enabling healthier lives VISION Ethics & Integrity To be an undisputed market Quality leader by providing accessible, affordable, timely and quality VALUES healthcare, diagnostics, applying Accountability insights and cu
Slide 14: DLPL Strategy for future growth
DLPL Strategy for future growth Significantly leverage the Enhance high-end test portfolio of strong digital infrastructure super-specialty & bundled test • Deployed AI, data analytics, machine learning • Created specialty verticals like Genevolve to focus on tools to elevate the patient experience
Slide 15: Leveraging digital infrastructure to make life easier for patient
Leveraging digital infrastructure to make life easier for patient New Website Launch Wallet • New age user intuitive website. • Senior Citizen Wallet: Wallet points on every • Responsive , mobile friendly web designs. booking for Senior Citizen Patients. • SEO friendly for improved customer reach •
Slide 16: Summary highlights – Technical Lab Operations
Summary highlights – Technical Lab Operations LACE and the centre Only lab in India to introduce the First lab to introduce the of excellence in Relaunched the Lipid Donor derived cell free DNA ONCOPRO TSO500 Reproductive panels incorporating the (LIQUID BIOPSY) technique for Comprehensive Genomic m
Slide 17: Genevolve: Genetic Testing Division
Genevolve: Genetic Testing Division Onco Genomics Successful completion of 3 years of Launch Wide Test offering with 160+ New Tests Neuro Genomics Wellness Genomics & Pharmacogenomics are upcoming segment Direct reach of 3000+ Doctors Reproductive Genomics Dedicated Business Development team for Gen
Slide 18: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 99.5% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.5% for Satellite Labs CAP accreditation 2 labs, NABL accreditation 36 Labs 100+ Quality Digitally enabled Real time
Slide 19: Quality Control
Quality Control Laboratory excellence Capability building Test Recommendation engine NABL 133 implementation D L Shah Gold Award for LPL Project ‘Improving Laboratory Performance by developing an in-house automated process to Risk Based Internal Audits monitor Quality control’ PROJECT NEEV- self lea
Slide 20: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Real time 30 minutes slot visibility & booking D2C- Automated lead management for the patient Digital ID card & ratings of Phlebo Auto Routing engine to dynamically to the patient allocate the booking to nearest available phlebotomist Variable model wh
Slide 21: Key ESG Initiatives
Key ESG Initiatives Use of Solar E-billing and e- Use of Electric Panels for Power; payment receipt bikes for sample addition of 50 KW to reduce paper collection solar plant at NRL usage Data centre Water saving virtualization to through treatment prevent heat and & reuse of CO2 emission wastewater
Slide 22: Savings of >1.3 million aliquots and >5210 tons of plastic waste
Savings of >1.3 million aliquots and >5210 tons of plastic waste in our lab – a strong commitment to sustainability Dr. Lal Pathlabs’ leadership vision focuses on continuous We reduced the need for aliquots by 93% by replacing our previous system configuration1,2 with new, improvement while maintain
Slide 23: Cyber Security Capability
Cyber Security Capability Data Loss • State-of-the-art data loss prevention technology to monitor and prevent the disclosure of information Prevention • Data classification platform for information labeling and handling according to severity of data • Rights management system to enable persistent da
Slide 24: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Group Chief Financial Officer Shankha Banerjee Munender Soperna Jai Prakash Meena Manoj Garg
Slide 25: Shareholding as of 30th September 2023
Shareholding as of 30th September 2023 24.8% FPI’s & NRI’s 54.6% Promoter and Promoter 14.4% Group Others 6.2% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 24 24 Classification: Restricted
Slide 26: Key Awards & Recognition
Key Awards & Recognition Diagnostic Chain of the Gold Award Year – West Top 100 Global Most Loved QCI – D. L. Shah Quality Business Standard Star SME Best Brands Healthcare GAPIO Excellence in Awarded by the Workplace 2023 Awards - 2022 of the year 2022 2022 Diagnostics Award 2022 prestigious Health
Slide 27: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests